Related Experiment Video

Updated: Jul 4, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms

Yuxia Wu1, Xiangyan Jiang1, Zeyuan Yu1

  • 1Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, China.

Recent Patents on Anti-Cancer Drug Discovery
|February 2, 2024
PubMed

Insights

Digestive tumors resist anti-programmed cell death protein (PD) therapies due to complex tumor microenvironments (TME). Understanding immune evasion, microbial interactions, metabolism, and epigenetics is key to developing effective treatments.

Area of Science:

  • Oncology
  • Immunology
  • Microbiology

Background:

  • Digestive system neoplasms are heterogeneous, often developing resistance to anti-programmed cell death protein (PD) therapies.
  • The tumor microenvironment (TME) significantly influences tumor progression, immune evasion, and drug resistance.
  • Gut microbiota and epigenetic modifications are critical components of the TME's role in cancer.

Purpose of the Study:

  • To elucidate mechanisms of drug resistance in digestive tumors.
  • To focus on immune-mediated resistance, microbial crosstalk, metabolism, and epigenetics.
  • To highlight the significance of the tumor immune microenvironment (TIME) and discuss novel therapeutic strategies.

Main Methods:

  • Review of current literature on digestive system neoplasms.
  • Analysis of mechanisms of drug resistance within the TME.
  • Exploration of the interplay between gut microbiota, epigenetics, and tumor immunity.

Main Results:

  • Digestive tumors exhibit complex resistance pathways involving immune suppression and metabolic reprogramming.
  • The gut microbiota critically influences therapeutic responses and tumor progression.
  • Epigenetic alterations contribute to immune escape and drug resistance in digestive cancers.

Conclusions:

  • Targeting the TME, including microbial and epigenetic factors, is crucial for overcoming resistance to anti-PD therapies.
  • Combination strategies involving cancer immune normalization hold promise for improving treatment outcomes.
  • Further research into the multifaceted TME is essential for developing effective therapies for digestive tumors.
Keywords:
Immunotherapy resistancePD-1/B7-H1anti-PD-1/PD-L1 therapydigestive system neoplasmsnormalization cancer immunotherapypancreatic cancer.

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

805
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

324

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
435